It was suspected but nothing formal put out by the company that I recall.
There was discussion a while ago that Sparsentan could be a competitor to DMX200 but this confirms that it can be used in combination for a better result than Sparsentan alone.
Few possible drivers - FSGS Phase 3, partnership deal/acquisition or something left field with the COVID trials.
It was suspected but nothing formal put out by the company that...
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
-0.005(1.43%) |
Mkt cap ! $189.6M | |||
| Open | High | Low | Value | Volume |
| 35.5¢ | 35.8¢ | 33.5¢ | $2.114M | 6.083M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 516070 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.5¢ | 3146 | 1 |
View Market Depth
| Last trade - 16.10pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
34.5¢ |
Change
-0.005 ( 0.83 %) |
||||
| Open | High | Low | Volume | ||
| 35.5¢ | 36.0¢ | 33.5¢ | 3852478 | ||
| Last updated 15.59pm 07/05/2024 ? | |||||
| DXB (ASX) Chart |